fda compounding semaglutide warning letters october 2025 Beyond the Headlines: to GLP-1 Compounders FDA unleashes warning letters to

Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a Meta-analysis of the EXSCEL and FIGHT trials

Certain Medications Antipsychotics, some antidepressants, corticosteroids, and other medications can partially counteract weight loss effects

Even the middle dose of 10mg produced 19.5% weight loss

For some patients, compounded semaglutide offers more flexible dosing or a cost-conscious alternative while maintaining therapeutic benefits

J.MulpuriY.LeggioL.SpigelmanI

[1] Importantly, GLP-1 medications are contraindicated in pregnancy and breastfeeding